Loading news...
ATLANTA, March 3, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate virtually at the upcoming Oppenheimer 36th Annual Healthcare MedTech & Services Conference. The Company's virtual fireside chat is scheduled to begin at 9:20 a.m.
Artivion, Inc. (AORT) Q4 2025 Earnings Call Transcript
Artivion (AORT) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to break-even earnings per share a year ago.
Fourth Quarter Highlights: GAAP revenue was $116.0 million in the fourth quarter of 2025 versus $97.3 million in the fourth quarter of 2024. For the full year, GAAP revenue was $441.3 million versus $388.5 million for the full year of 2024.
Artivion (NYSE: AORT - Get Free Report) is expected to announce its Q4 2025 results after the market closes on Thursday, February 12th. Analysts expect the company to announce earnings of $0.14 per share and revenue of $116.4190 million for the quarter. Investors can check the company's upcoming Q4 2025 earning summary page for the latest
1-Year Data from Endospan's NEXUS TRIOMPHE IDE Trial Demonstrate High Patient Survival with Low Morbidity 2-Year Data from the AMDS PERSEVERE IDE Trial Further Demonstrate the Persistent Clinical Benefit of AMDS ATLANTA, Feb. 2, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of new clinical data from Endospan's NEXUS TRIOMPHE IDE trial and its AMDS PERSEVERE IDE trial at the 62nd Annual Meeting of the Society of Thoracic Surgeons in New Orleans, Louisiana. The NEXUS TRIOMPHE IDE trial presentation of 94 patients highlighted 94% patient survival from lesion related death and 91% freedom from disabling stroke at 1-year post-treatment in this high-risk patient group.
ATLANTA, Jan. 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter 2025 financial results will be released on Thursday, February 12, 2026, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.
Summary HARBOR CAPITAL ADVISORS, INC. reduced its stake in Artivion Inc (AORT) by 1.61%, selling 2 shares and holding 122 shares valued at about $10,00
Shares of Artivion, Inc. (NYSE: AORT - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the nine brokerages that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and seven have assigned a buy rating to the
Artivion continues to outperform the med-tech sector, driven by strong execution in stent grafts and On-X valve businesses. Recent clinical updates for the AMDS prosthesis reinforce its safety and efficacy, supporting further adoption and de-risking full commercialization. I expect double-digit long-term revenue growth, expanding EBITDA margins, and a fair value in the high-$50s, justifying a bullish stance.
Squarepoint Ops LLC bought a new position in Artivion, Inc. (NYSE: AORT) during the undefined quarter, according to its most recent filing with the SEC. The institutional investor bought 21,362 shares of the company's stock, valued at approximately $664,000. Other hedge funds and other institutional investors have also added to or reduced their
Artivion, Inc. (NYSE: AORT - Get Free Report) has earned an average recommendation of "Moderate Buy" from the nine analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and seven have assigned a buy recommendation to the company.
Here is how Artivion (AORT) and Pacific Biosciences of California (PACB) have performed compared to their sector so far this year.
Representative Gilbert Ray Cisneros, Jr. (D-California) recently sold shares of Artivion, Inc. (NYSE: AORT). In a filing disclosed on November 18th, the Representative disclosed that they had sold between $1,001 and $15,000 in Artivion stock on October 9th. The trade occurred in the Representative's "150 MAIN STREET TRUST > BANK OF AMERICA" account. Representative Gilbert Ray
Bridger Management LLC lifted its position in shares of Artivion, Inc. (NYSE: AORT) by 106.2% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 132,588 shares of the company's stock after purchasing an additional 68,288 shares during the quarter. Artivion makes up
Class A shares of the Alger Weatherbie Specialized Growth Fund underperformed the Russell 2500 Growth Index during the third quarter of 2025. Semtech Corporation (SMTC), Impinj Inc. (PI), and Artivion, Inc. (AORT) were among the top contributors to performance. SPS Commerce, Inc. (SPSC), Palomar Holdings, Inc. (PLMR), and Vertex, Inc. (VRTX) were among the top detractors from performance.
Artivion, Inc. ( AORT ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Pat MacKin Lance Berry - EVP, COO, CFO & Treasurer Conference Call Participants Lynn Lewis - Gilmartin Group LLC John McAulay - Stifel, Nicolaus & Company, Incorporated, Research Division Frank Takkinen - Lake Street Capital Markets, LLC, Research Division Suraj Kalia - Oppenheimer & Co. Inc., Research Division Joseph Conway - Needham & Company, LLC, Research Division Daniel Stauder - Citizens JMP Securities, LLC, Research Division Jeffrey Cohen - Ladenburg Thalmann & Co. Inc., Research Division Presentation Operator Good afternoon, and welcome to the Artivion Third Quarter 2025 Earnings Call. [Operator Instructions].
Artivion (AORT) came out with quarterly earnings of $0.16 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.12 per share a year ago.
Third Quarter Highlights: Achieved revenue of $113.4 million in the third quarter of 2025 versus $95.8 million in the third quarter of 2024, an increase of 18% on a GAAP basis and 16% on a non-GAAP constant currency basis Net income was $6.5 million, or $0.13 per fully diluted share, and non-GAAP net income was $7.9 million, or $0.16 per fully diluted share in the third quarter of 2025 Adjusted EBITDA increased 39% to $24.6 million in the third quarter of 2025 compared to $17.7 million in the third quarter of 2024 Enrolled first patient in ARTIZEN U.S. Investigational Device Exemption trial for Arcevo ATLANTA , Nov. 6, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the third quarter ended September 30, 2025. "Our third quarter performance was exceptionally strong as we made progress across each of our strategic initiatives while delivering 16% constant currency revenue growth.
ATLANTA , Nov. 6, 2025 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the treatment of the first patient in the ARTIZEN pivotal trial, evaluating the safety and effectiveness of the Arcevo™ LSA Hybrid Stent Graft System ("Arcevo LSA") in the treatment of acute and chronic arch pathologies. The trial is designed to support the Company's forthcoming application to the U.S. Food and Drug Administration (FDA) for Premarket Approval (PMA) of Arcevo LSA.